AmberGen and Mass General License Two Novel Autoantigen Biomarkers for Autoimmune Liver Disease to INOVA Diagnostics | Biomarker Commons

Links shared publicly online about this topic.

  • 34
    total visits

AmberGen and Mass General License Two Novel Autoantigen Biomarkers for Autoimmune Liver Disease to INOVA Diagnostics | Biomarker Commons

biomarkercommons.org —

Two novel autoantigen biomarkers for the autoimmune liver disease Primary Biliary Cirrhosis (PBC), discovered by AmberGen, Inc., in collaboration with the Massachusetts General Hospital (MGH), were exclusively licensed to INOVA Diagnostics, Inc., part of the Werfen Group, and a world-leader in clinical assays for autoimmune disease.

View full resource at biomarkercommons.org

Tags:

  • Share

Most Recently Shared on March 15, 2012 at 12:00 pm By:

wjjessen Walter Jessen, PhD

Advertisement